

Glenmark Pharma Q4 net declines to ₹43 crore

Glenmark Pharmaceuticals fourth-quarter profit declined as it recorded a one-time provision of ₹217.53 crore as potential damages to be paid on failing to enforce the validity of its generic version of the hypertension drug, Tarka. The company reported a consolidated net profit of ₹43.41 crore for the quarter ended March 31. The company had posted profit of ₹175.12 crore in Q4FY13. Consolidated net sales jumped 26% year-on-year to ₹1,681.74 crore.

STAKEHOLDERS

BRANDS

13.5.14

Company

TJ, NIC
22.5.14